Our Q3 2014 Outlook Report highlighted several high-impact catalysts that resulted in large stock price changes. The results of all of our Q3 catalysts can be found on Page 4 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 85% of catalyst outcomes in Q3 2014.

In this quarter's report, we cover catalysts from 22 drugs and 2 devices and have included a list of Large Impact catalysts in the drug, device/diagnostic, and natural resource areas through December 2014 from our sister product, CatalystTracker. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.